A Phase 1, Randomized, Double Blind, Placebo-Controlled, Parallel Cohort, Single Dose Escalation And Multiple Dose Study In Japanese Healthy Subjects, And Open Label, Single Dose Escalation Study In Western Healthy Subjects To Investigate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04971729.
Latest Information Update: 11 May 2022
At a glance
- Drugs Ertugliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 16 Mar 2019 Pharmacokinetic results presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 04 Apr 2011 Actual end date (1 Feb 2011) added as reported by ClinicalTrials.gov.
- 04 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.